Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
Hoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Bruggeman SWM, Kornblau SM, Horton TM. Hoff FW, et al. Among authors: horton tm. Blood. 2021 Feb 25;137(8):1050-1060. doi: 10.1182/blood.2020005208. Blood. 2021. PMID: 32959058 Free PMC article. Clinical Trial.
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL. Horton TM, et al. Mol Cancer Ther. 2009 Aug;8(8):2232-42. doi: 10.1158/1535-7163.MCT-09-0142. Epub 2009 Aug 11. Mol Cancer Ther. 2009. PMID: 19671751 Free PMC article.
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA; ALLNA 2008 Conference. Horton TM, et al. Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8. doi: 10.1002/pbc.22414. Pediatr Blood Cancer. 2010. PMID: 20127846 Free PMC article.
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. Muscal JA, et al. Among authors: horton tm. Pediatr Blood Cancer. 2013 Mar;60(3):390-5. doi: 10.1002/pbc.24271. Epub 2012 Aug 9. Pediatr Blood Cancer. 2013. PMID: 22887890 Free PMC article. Clinical Trial.
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI. Cooper TM, et al. Among authors: horton tm. Cancer. 2014 Aug 15;120(16):2482-9. doi: 10.1002/cncr.28674. Epub 2014 Apr 25. Cancer. 2014. PMID: 24771494 Free PMC article. Clinical Trial.
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA. Horton TM, et al. Pediatr Blood Cancer. 2014 Oct;61(10):1754-60. doi: 10.1002/pbc.25117. Epub 2014 Jun 29. Pediatr Blood Cancer. 2014. PMID: 24976003 Free PMC article. Clinical Trial.
A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.
Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R. Miller TP, et al. Among authors: horton tm. Leuk Lymphoma. 2016 Jul;57(7):1567-74. doi: 10.3109/10428194.2015.1088652. Epub 2016 Jan 4. Leuk Lymphoma. 2016. PMID: 26727639 Free PMC article.
Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.
Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Miller TP, et al. Among authors: horton tm. J Clin Oncol. 2016 May 1;34(13):1537-43. doi: 10.1200/JCO.2015.65.5860. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884558 Free PMC article.
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
Niewerth D, Kaspers GJ, Jansen G, van Meerloo J, Zweegman S, Jenkins G, Whitlock JA, Hunger SP, Lu X, Alonzo TA, van de Ven PM, Horton TM, Cloos J. Niewerth D, et al. Among authors: horton tm. J Hematol Oncol. 2016 Sep 6;9(1):82. doi: 10.1186/s13045-016-0312-z. J Hematol Oncol. 2016. PMID: 27599459 Free PMC article. Clinical Trial.
106 results